Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience

[1]  M. Bertagnolli,et al.  Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance). , 2017 .

[2]  E. Van Cutsem,et al.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials , 2017, JAMA oncology.

[3]  S. Barni,et al.  Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[4]  Carl Virtanen,et al.  Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial , 2016, Genome Medicine.

[5]  J. Meyerhardt,et al.  Impact of primary (1{o}) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). , 2016 .

[6]  Jeffrey S. Morris,et al.  Association of primary (1{degrees}) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor ({alpha}EGFR) therapy. , 2016 .

[7]  H. Friess,et al.  Right Sided Colon Cancer as a Distinct Histopathological Subtype with Reduced Prognosis , 2016, Digestive Surgery.

[8]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[9]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[10]  Jin-Ling Tang,et al.  Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases , 2015, Scientific Reports.

[11]  A. Barzi,et al.  Distinct Gene Expression Profiles of Proximal and Distal Colorectal Cancer: Implications for Cytotoxic and Targeted Therapy , 2014, The Pharmacogenomics Journal.

[12]  Mef Nilbert,et al.  The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis , 2014, Acta oncologica.

[13]  W. Scheithauer,et al.  Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. , 2014 .

[14]  Savita Shrivastava,et al.  Validation of a next-generation sequencing assay for clinical molecular oncology. , 2014, The Journal of molecular diagnostics : JMD.

[15]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[16]  A. McCullough.  Comprehensive molecular characterization of human colon and rectal cancer , 2013 .

[17]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[18]  A. Viale,et al.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Guchelaar,et al.  Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. , 2011, The oncologist.

[20]  T. Price,et al.  Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Y. Yatabe,et al.  BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer , 2011, British Journal of Cancer.

[23]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[26]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[27]  P. Boyle,et al.  ABC of colorectal cancer: Epidemiology , 2000, BMJ.

[28]  P. Holt,et al.  Are right- and left-sided colon neoplasms distinct tumors? , 1997, Digestive diseases.

[29]  J. Bufill,et al.  Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. , 1990, Annals of internal medicine.